GLP-1 weight-loss drugs linked to hair loss: what Canadian patients need to know

This article is for informational purposes only and is not medical advice. Consult your Canadian healthcare provider about your situation.

---

Three studies published in July 2026 found that GLP-1 receptor agonists, a drug class that includes semaglutide (sold in Canada as Ozempic and Wegovy, by Novo Nordisk) and tirzepatide (sold in Canada as Mounjaro and Zepbound, by Eli Lilly), carry a statistically higher risk of alopecia than other common diabetes and weight-management drugs, though the absolute numbers remain low. The largest of the three, published July 22 in The BMJ by researchers at the University of Pennsylvania, found that at two or more years of treatment, GLP-1 users had 37% higher odds of a new alopecia diagnosis compared with SGLT-2 inhibitor users and 68% higher odds compared with DPP-4 inhibitor users, across groups of 11,000 to 15,000 patients each.

For Canadians currently taking or considering these drugs, the finding is relevant but not a reason to stop treatment without speaking to a prescriber. Health Canada has approved semaglutide (Ozempic for type 2 diabetes, Wegovy for chronic weight management) and tirzepatide (Mounjaro for type 2 diabetes; Zepbound was approved by the US FDA but as of this writing has not received a Health Canada notice of compliance for obesity). Neither drug's Canadian product monograph currently lists alopecia as a recognized adverse effect, and Health Canada has not issued updated guidance in response to these studies. The Society of Obstetricians and Gynaecologists of Canada (SOGC) has not yet released a position statement on GLP-1-associated hair loss.

What this means in Canada

Semaglutide and tirzepatide are available by prescription across all provinces, but coverage varies considerably. In Ontario, Ozempic is listed on the Ontario Drug Benefit (ODB) formulary for type 2 diabetes with prior authorization; Wegovy is not publicly covered under OHIP as of mid-2026 and must be paid out of pocket or through private insurance, at roughly CAD $350–$450 per month. In Quebec, the Régie de l'assurance maladie du Québec (RAMQ) covers Ozempic for diabetes but not Wegovy for obesity. British Columbia's PharmaCare and Alberta's Alberta Health Care Insurance Plan (AHCIP) follow similar patterns: diabetes indication covered, obesity indication generally not. Patients using these drugs through Canadian telehealth platforms such as Felix, Cleo, Science & Humans (scienceandhumans.com), or Maple are typically paying privately for the obesity indication and may not have a specialist monitoring them for side effects like hair loss.

US-based platforms such as Hone Health and Midi do not serve Canadian patients and are not relevant here.

What changed

Before these three papers, hair loss was widely attributed to rapid weight loss itself, a well-documented phenomenon called telogen effluvium, where metabolic stress pushes hair follicles into a resting phase. That explanation is not wrong, but the new data complicate it.

The University of Pennsylvania BMJ study compared GLP-1 users against two other drug classes used for the same conditions, controlling for the fact that all groups were managing diabetes or obesity. The GLP-1 group still had meaningfully higher alopecia rates, which suggests something beyond weight loss alone may be at work.

A second study in the Journal of the American Academy of Dermatology, with more than one million participants worldwide, found significantly higher risks of multiple alopecia subtypes with GLP-1 drugs compared with metformin, the most commonly prescribed first-line diabetes drug in Canada.

A third study, a preprint submitted for peer review from analytics firm nference, compared 11,046 tirzepatide users with the same number of semaglutide users. New-onset alopecia occurred in 4.24% of tirzepatide users versus 3.33% of semaglutide users. Among women specifically, those rates were 5.44% with tirzepatide and 3.63% with semaglutide. Notably, the tirzepatide signal held even after accounting for how much weight patients lost and what dose they received, which points away from weight loss as the sole driver. The nference researchers also found that patients with thyroid disease or other endocrine disorders had higher alopecia rates, suggesting that baseline hormonal or autoimmune factors may interact with the drug's mechanism.

"This supports more individualized counseling and surveillance rather than a generic message that weight loss itself inevitably causes hair loss," said Venky Soundararajan, who led the nference study.

What Canadian patients should know

Alopecia is a broad term covering several types of hair loss. The studies do not specify whether the observed cases were diffuse thinning (most consistent with telogen effluvium), patchy loss (alopecia areata, which has an autoimmune component), or androgenetic hair loss. That distinction matters clinically and is not yet resolved in the published data.

The absolute rates in the BMJ study were 3 to 9 per 1,000 people per year. That is low. For most patients whose prescriber has recommended a GLP-1 drug for diabetes management or significant obesity-related health risk, the cardiovascular and metabolic benefits documented in trials such as SUSTAIN and SURMOUNT are likely to outweigh a low-probability cosmetic side effect. But patients who are already managing thyroid conditions, autoimmune disease, or existing hair thinning may want to raise this specifically with their doctor or endocrinologist before starting or continuing treatment.

If you are already on semaglutide or tirzepatide and have noticed increased shedding, a few practical points apply. Hair loss from telogen effluvium typically begins two to four months after a metabolic stressor and is often reversible once the body stabilizes. A dermatologist can distinguish between types of alopecia and advise on whether the drug, the weight loss, a nutritional gap (iron and zinc deficiencies are common during rapid weight loss), or an underlying condition is the primary driver. Stopping the drug without medical advice is not recommended, particularly for patients using it to manage type 2 diabetes.

Patients accessing GLP-1 drugs through telehealth platforms, where follow-up may be less frequent than in a specialist clinic, should proactively flag new hair shedding at their next check-in rather than waiting for a scheduled review.

Limitations and open questions

All three studies have methodological constraints worth noting. The BMJ and JAAD studies are observational, meaning they identify associations, not causes. Confounding is possible: GLP-1 users may differ from SGLT-2 or metformin users in ways the researchers could not fully control, including baseline weight, hormonal status, or concurrent medications.

The nference preprint has not yet completed peer review and should be treated with corresponding caution. Its sample was drawn from US electronic health records, and it is not clear how well that population maps onto Canadian patients, who may differ in baseline thyroid disease prevalence, dietary patterns, or drug formulations available.

Neither Health Canada nor the Canadian Institutes of Health Research (CIHR) has funded or announced a Canadian-specific study on this question. The SOGC has not commented. Whether tirzepatide's higher alopecia signal compared with semaglutide reflects a pharmacological difference between the two drugs, or simply that tirzepatide produces faster or greater weight loss, is not yet established.

What is clear is that hair loss with GLP-1 drugs is real, measurable, and more common than with alternative drug classes. It is also, in most cases, low in absolute probability and potentially reversible. Patients deserve that full picture from their prescribers, not a dismissal and not an alarm.

---

This article is for informational purposes only and is not medical advice. Consult your Canadian healthcare provider about your situation.

Editorial note

Hormone Journal articles are written by our editorial team and reviewed against published clinical guidelines, with a focus on Canadian patient access. We do not promote specific clinics or providers.